Want to see NRXP full AI Analyst Report?
NRXP Stock Chart & Stats
$3.75
-$0.36(-8.76%)
At close: 4:00 PM EDT
$3.75
-$0.36(-8.76%)
Day’s Range― - ―
52-Week Range$1.62 - $5.06
Previous CloseN/A
Volume791.73K
Average Volume (3M)475.66K
Market Cap
$154.13M
Enterprise Value$128.55
Total Cash (Recent Filing)$26.69M
Total Debt (Recent Filing)$1.25M
Price to Earnings (P/E)―
Beta0.92
Next Earnings
Nov 16, 2026EPS Estimate
-0.11Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.74
Shares Outstanding43,295,770
10 Day Avg. Volume509,446
30 Day Avg. Volume475,656
Financial Highlights & Ratios
PEG Ratio0.05
Price to Book (P/B)-3.64
Price to Sales (P/S)47.35
P/FCF Ratio-4.11
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$27.50Price Target Upside633.33% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.38
Revenue Forecast (FY)$10.20M
Bulls Say, Bears Say
Bulls Say
Early Commercial Revenue GrowthRevenue growth indicates early commercial traction and expanding product activity. If sustained, a larger revenue base could gradually improve operating leverage and reduce dependence on financing as the company advances its CNS portfolio.
Ketamine Regulatory ProgressThe preservative-free ketamine program is approaching a potential 2026 approval with launch inventory already ordered. Regulatory clearance could create an earlier commercial revenue stream and establish a platform in a supply-constrained market.
Expanded Pipeline And Strategic PartnershipsPipeline expansion and government-linked development opportunities diversify the company beyond a single product candidate. The programs could increase addressable markets and provide external validation, although clinical and contracting milestones remain necessary.
Bears Say
Persistent Losses And Cash BurnThe company remains far from profitability, with development and commercial preparation costs substantially exceeding revenue. Continued cash consumption limits financial flexibility and means successful launches or additional funding are needed to sustain operations.
Negative Equity And Fragile Capital StructureNegative equity reflects accumulated losses and weakens the balance sheet despite relatively low reported debt. This reduces resilience against setbacks and increases reliance on equity issuance, partnerships, or other external capital.
Funding And Execution DependenceThe stated runway creates a structural need for commercial milestones or further financing beyond the next year. Regulatory approvals, military contracting, government funding, manufacturing, and trial execution could all affect timing and capital requirements.
NRX Pharmaceuticals News
NRXP FAQ
What was NRX Pharmaceuticals’s price range in the past 12 months?
NRX Pharmaceuticals lowest stock price was $1.62 and its highest was $5.05 in the past 12 months.
What is NRX Pharmaceuticals’s market cap?
NRX Pharmaceuticals’s market cap is $154.13M.
When is NRX Pharmaceuticals’s upcoming earnings report date?
NRX Pharmaceuticals’s upcoming earnings report date is Nov 16, 2026 which is in 84 days.
How were NRX Pharmaceuticals’s earnings last quarter?
NRX Pharmaceuticals released its earnings results on Aug 17, 2026. The company reported -$0.44 earnings per share for the quarter, missing the consensus estimate of -$0.107 by -$0.333.
Is NRX Pharmaceuticals overvalued?
According to Wall Street analysts NRX Pharmaceuticals’s price is currently Undervalued.
Does NRX Pharmaceuticals pay dividends?
NRX Pharmaceuticals does not currently pay dividends.
What is NRX Pharmaceuticals’s EPS estimate?
NRX Pharmaceuticals’s EPS estimate is -0.11.
How many shares outstanding does NRX Pharmaceuticals have?
NRX Pharmaceuticals has 43,295,770 shares outstanding.
What happened to NRX Pharmaceuticals’s price movement after its last earnings report?
NRX Pharmaceuticals reported an EPS of -$0.44 in its last earnings report, missing expectations of -$0.107. Following the earnings report the stock price went up 4.893%.
Which hedge fund is a major shareholder of NRX Pharmaceuticals?
Currently, no hedge funds are holding shares in NRXP
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
NRX Pharmaceuticals Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$27.50 (633.33% Upside)
$27.50 (633.33% Upside)
Blogger Sentiment
Neutral
NRXP Sentiment 100%
Sector Average 61%
Sector Average 61%
Hedge Fund Trend
Decreased
By 3.0M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 1.0%
Last 30 Days ▲ 3.2%
Last 30 Days ▲ 3.2%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
164.80%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
606.08%
Trailing 12-Months
Company Description
NRX Pharmaceuticals
NRx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm focused on developing innovative therapies for disorders of the central nervous system and critical lung diseases. Its product portfolio features ZYESAMI, an experimental medication that has successfully completed Phase IIb/III clinical trials for treating respiratory failure associated with COVID-19. Additionally, the company is advancing NRX-100 and NRX-101, a pair of oral therapeutics designed to address bipolar depression, specifically in patients exhibiting acute or sub-acute suicidal thoughts and behaviors. Established in 2015, NRx Pharmaceuticals is headquartered in Wilmington, Delaware.
NRXP Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed significant strategic and technical progress across multiple fronts: near-term commercialization steps (ANDA and launch-stock orders), a strengthened balance sheet (cash up ~242%), a materially expanded development pipeline via the GeNeuro acquisition, and a high-impact DARPA/military partnership with a 400-patient SPARC-TMS trial. These positives are tempered by ongoing net operating losses (operating loss up ~48.7%), regulatory/contracting uncertainties, dependence on nondilutive government funding, and the need for further financing or successful commercial milestones beyond the ~1-year cash runway. Overall, the tone is cautiously optimistic: strong strategic wins and funding momentum outweigh current financial and execution risks, but key approvals, contracts and trial execution remain critical near-term milestones.View all NRXP earnings summariesNRXP Stock 12 Month Forecast
Average Price Target
$27.50
▲(633.33% Upside)
Technical Analysis
CervoMed
―
―
Werewolf Therapeutics
―
OKYO Pharma Limited Sponsored ADR
―
CAMP4 Therapeutics Corporation
―
Ownership Overview
8.72%
Insiders
3.12% Mutual Funds
11.35% Other Institutional Investors
71.03% Public Companies and
Individual Investors